A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals

A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Adults Who is COVID-19 naïve or Had Previous COVID-19 Infection or Completed Inactivated or mRNA COVID-19 Vaccination.

This is a Phase I, open label, dose-escalation study of three dose levels of the SARS-CoV-2 spike antigen administered intramuscularly (IM) in combination with a fixed dosage of PIKA adjuvant vaccine to evaluate the safety, tolerability, and immunogenicity of PIKA COVID-19 vaccine candidate in healthy individuals aged 18 years and above. The study will comprise of two arms. Arm A will include subjects who never been infected with COVID-19 or with a history of COVID-19 infection for not less than 6 months prior to study participation and Arm B will include subjects who will be receiving PIKA vaccine as a booster vaccination dose to COVID-19 primary vaccination of inactivated or mRNA Covid 19 vaccines.

Study Overview

• Status: Completed
• Conditions: COVID-19 Pandemic
• Intervention / Treatment: Biological: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A; Biological: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B

Detailed Description

This is a Phase I, open label, dose-escalation study of three dose levels of the SARS-CoV-2 spike antigen administered intramuscularly (IM) in combination with a fixed dosage of PIKA adjuvant vaccine to evaluate the safety, tolerability, and immunogenicity of PIKA COVID-19 vaccine candidate in healthy individuals aged 18 years and above. The study will comprise of two arms. Arm A will include subjects who had never been infected with COVID-19 or with a history of COVID-19 infection for not less than 6 months prior to study participation and Arm B will include subjects who will be receiving PIKA vaccine as a booster vaccination dose to COVID-19 primary vaccination of inactivated or mRNA Covid 19 vaccines.

Arm A: There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. A total of 45 subjects will be enrolled in Arm A. Subjects in Group 1-3 will receive two doses of PIKA COVID-19 vaccine via IM administration on Days 0 and 7. Fifteen eligible subjects in each dose group.

Arm B: There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. A total of 90 subjects will be enrolled in Arm B which will be divided into Arm B1 (45 subjects) and Arm B2 (45 subjects). Arm B1 will enroll subjects who received Inactivated vaccines and will comprise of 15 subjects per dose (45 subjects). Arm B2 will enroll subjects who received mRNA vaccines and will comprise of 15 subjects per dose (45 subjects). Subjects in Group 1-3 of Arm B1 and Arm B2 will receive one booster dose of PIKA COVID-19 vaccine via IM administration on Days 0.

• Study Type: Interventional
• Enrollment (Actual): 135
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Arab Emirates
  • Dubai, United Arab Emirates
    • Al Kuwait Hospital (Al Baraha Hospital)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria

Inclusion Criteria of Arm A:

1. Male and female healthy volunteers.
2. Age ≥18 years on Study Day 0.
3. Judged by the investigator to be healthy on the basis of medical history, physical examination and vital signs performed at screening.
4. Able to provide informed consent.
5. Able and willing to comply with all study procedures over follow-up period of approximately 6 months.
6. For more inclusion criteria, please contact the investigator or sponsor.

Inclusion Criteria of Arm B:

Male and female healthy volunteers.

1. Received complete primary series of COVID-19 Inactivated Vaccines not less than 6 months or Received complete primary series of COVID-19 mRNA Vaccines not less than 6 month.
2. Age ≥18 years on Study Day 0.
3. Judged by the investigator to be healthy on the basis of medical history, physical examination and vital signs performed at screening.
4. Able to provide informed consent .
5. Able and willing to comply with all study procedures over follow-up period of approximately 6 months.
6. For more inclusion criteria, please contact the investigator or sponsor.

Exclusion Criteria:

Exclusion Criteria of Arm A:

1. History of COVID-19 of less than 6 months prior to enrollment
2. Received partial or complete course of any type of COVID-19 vaccine.
3. History of close contact with a person infected or suspected of COVID-19 not less than 14 days prior to study enrollment.
4. Positive test for SARS-CoV-2 infection, including but not limited to RT-PCR /Rapid Antigen Test at screening, before the first dose (Day 0) and before the second dose (Day 7).
5. For more exclusion criteria, please contact the investigator or sponsor.

Exclusion Criteria of Arm B:

1. History of close contact with a person infected or suspected of COVID-19 not less than 14 days prior to study enrollment.
2. Positive test for SARS-CoV-2 infection, including but not limited to RT-PCR/RAT at screening, before the first dose (Day 0) .
3. Have received three and more doses of COVID-19 vaccine.
4. Pregnant or breastfeeding or intending to become pregnant or father children within the projected duration of the trial.
5. For more exclusion criteria, please contact the investigator or sponsor.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: Primary Immunization; There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. A total of 45 subjects will be enrolled in Arm A. Subjects in Group 1-3 will receive two doses of PIKA COVID-19 vaccine via IM administration on Days 0 and 7.	Biological: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A; receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.
Experimental: Arm B1: Booster Immunization 1; There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B1 will enroll subjects who received Inactivated vaccines and will comprise of 15 subjects per dose. In arm B1, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.	Biological: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B; receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
Experimental: Arm B2: Booster Immunization 2; There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B2 will enroll subjects who received mRNA vaccines and will comprise of 15 subjects per dose. In arm B2, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.	Biological: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B; receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Solicited local adverse events,	Incidence of solicited local adverse events (AEs).	7 days after each vaccination.
Solicited systemic AEs	Incidence of solicited systemic AEs.	7 days after each vaccination.
Unsolicited AEs	Incidence of unsolicited AEs.	28 days after each vaccination.
Serious adverse events (SAEs) including Suspected Unexpected Serious Adverse Reaction (SUSARs)	Incidence of serious adverse events (SAEs) including Suspected Unexpected Serious Adverse Reaction (SUSARs).	through study completion, an average of 6 months.
Medically Attended AEs (MAAEs)	Incidence of Medically Attended AEs (MAAEs).	through study completion, an average of 6 months.
AEs of special interest (AESIs)	Incidence of AEs of special interest (AESIs).	through study completion, an average of 6 months.

Collaborators and Investigators

• Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd.
• Investigators: Study Director: Yuan Liu, Ph.D, Yisheng Biopharma CO., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): October 18, 2021
• Primary Completion (Actual): May 15, 2022
• Study Completion (Actual): September 15, 2022

Study Registration Dates

• First Submitted: March 20, 2022
• First Submitted That Met QC Criteria: March 29, 2022
• First Posted (Actual): March 31, 2022

Study Record Updates

• Last Update Posted (Estimate): December 22, 2022
• Last Update Submitted That Met QC Criteria: December 20, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Immunologic Factors; Protease Inhibitors; Serine Proteinase Inhibitors; Trypsin Inhibitors; Vaccines; Somatomedin B
• Other Study ID Numbers: YS-009

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No